Nuvectis signed a deal with Haisco for exclusive ex-China rights on two new medicines.
Nuvectis has secured exclusive rights outside China to NXP100, an experimental once-daily oral drug for immune-related diseases, and NXP200, which is a cancer treatment targeting a type of mutation called BRAF.
China's Haisco will receive upfront and near-term payments totaling up to $40 million and is eligible to receive up to $1.42 billion in additional milestone payments, as well as tiered royalties on future net sales.
The deal "meaningfully expands the Nuvectis story from a more focused oncology company...into a broader late-stage clinical development company with both complement and oncology growth drivers," H.C. Wainwright analyst Joseph Pantginis said.
He added that NXP100 "emerges as a key value driver" given its late-stage development and potential across multiple diseases.
NXP100 is under regulatory review in China for paroxysmal nocturnal hemoglobinuria, a rare disorder where red blood cells break down, after studies showed higher hemoglobin levels and reduced need for transfusions compared with AstraZeneca's
Nuvectis said the drug is in late-stage development for IgA nephropathy, a kidney disease caused by immune deposits, following positive mid-stage data showing reduced protein in urine.
The company said NXP200 is designed to treat cancers driven by changes in the BRAF gene, which help tumors grow, including lung, colorectal and brain tumors, while avoiding resistance seen with older therapies.
Early data showed durable responses across several tumor types, including brain cancers, Nuvectis said.
The company added that NXP200 is in an early-stage study in China, with a newer version showing improved drug exposure.
Haisco will retain rights in China and some Asian markets as the companies work to advance the programs globally.
A total of 5,215 clinical trials were registered on China’s Drug Clinical Trial Registration and Information Disclosure Platform in 2025, up 6.4 percent from the year before and doubling from 2020
72% or 2,171 of the clinical trial registrations last year were for Class 1 innovative drugs, nearly 38 percent of which were anti-tumor treatments
Class 1 innovative drugs are first-in-class global innovative pharmaceuticals
The high volume of Phase 1 clinical trials reflects China’s capacity for original pharmaceutical innovation
Nearly 14 percent of last year’s new clinical trial registrations were for multi-regional tests, covering sites across more than 70 countries and regions
Leading Europe and America! my country launches the world's first solid tumor treatment: targeting stomach cancer, etc., priced at 990,000 yuan per dose.
